|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Salarius Pharmaceuticals, Inc (SLRX) |
|
|
$0.46 0.00 (0.00%) as of 4:30 Fri 8/15
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,440,000 |
| Market
Cap: |
664.99(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4527 - $3.67 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline consists of two compounds: seclidemstat (SP-2577), a small molecular inhibitor and SP-3164, a small molecular protein degrader. SP-2577 is a small-molecule lysine specific demethylase 1 (LSD1) inhibitor with a scaffold. LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth. SP-3164 is a cereblon binding molecular glue. SP-3164 degrades transcription factors IKZF1 and IKZF3, along with other proteins, resulting in both direct anti-cancer activity and immune-modulating properties. SP-3164 has activity in both hematologic and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-08-21 |
2025-05-20 |
2024-11-19 |
2023-11-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2025-11-20 |
4 |
B |
$0.80 |
$16,000 |
D/D |
20,000 |
20,177 |
2.74 |
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
6,432 |
21,851 |
|
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,300 |
48,019 |
|
- |
|
| Lammers Paul |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
1,718 |
|
- |
|
| Mcvicar William K. |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
1,788 |
|
- |
|
| Lieber Jonathan I |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
2,940 |
|
- |
|
| Mccreedy Bruce J Jr. |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
1,788 |
|
- |
|
| Hanish Arnold C |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
1,440 |
|
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
15,419 |
|
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
33,719 |
|
- |
|
| Burleson Tess |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,440 |
2,722 |
|
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2022-11-03 |
4/A |
A |
$1.73 |
$4,670 |
D/D |
2,693 |
13,719 |
|
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2022-11-03 |
4/A |
A |
$1.73 |
$2,580 |
D/D |
1,488 |
7,419 |
|
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2022-11-03 |
4/A |
A |
$1.73 |
$12,682 |
D/D |
7,314 |
13,245 |
|
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2022-11-03 |
4/A |
A |
$1.73 |
$17,340 |
D/D |
10,000 |
21,026 |
|
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2022-11-03 |
4 |
A |
$1.73 |
$17,340 |
D/D |
10,000 |
285,674 |
|
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2022-11-03 |
4 |
A |
$1.73 |
$12,682 |
D/D |
7,314 |
155,633 |
|
- |
|
| Lieber Jonathan I |
Director |
– • – |
2022-06-07 |
4 |
B |
$0.19 |
$7,016 |
D/D |
37,500 |
37,500 |
2.39 |
- |
|
| Burleson Tess |
Director |
– • – |
2022-06-07 |
4 |
B |
$0.18 |
$4,986 |
D/D |
27,700 |
32,050 |
2.31 |
- |
|
| Mcvicar William K. |
Director |
– • – |
2022-06-06 |
4 |
B |
$0.19 |
$5,000 |
I/I |
26,553 |
26,553 |
2.1 |
- |
|
| Hanish Arnold C |
Director |
– • – |
2022-06-03 |
4 |
B |
$0.18 |
$5,152 |
I/I |
28,000 |
46,350 |
2.1 |
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2022-05-31 |
4 |
B |
$0.18 |
$5,040 |
D/D |
28,000 |
148,319 |
2.74 |
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2022-05-26 |
4 |
B |
$0.18 |
$3,987 |
I/I |
21,900 |
303,574 |
2.58 |
- |
|
| Arthur David J. |
Chief Executive Officer |
• • – |
2022-05-26 |
4 |
B |
$0.18 |
$3,997 |
D/D |
22,000 |
281,674 |
2.73 |
- |
|
| Rosenblum Mark J |
Exec VP Finance, CFO |
• – – |
2022-05-03 |
4 |
A |
$0.19 |
$1,863 |
D/D |
10,000 |
120,319 |
|
- |
|
116 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
